{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360855570161878656.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1128/jvi.00187-08"}},{"identifier":{"@type":"URI","@value":"https://journals.asm.org/doi/pdf/10.1128/JVI.00187-08"}}],"dc:title":[{"@value":"Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>Although the human transmission of avian H5N1 virus remains low, the prevalence of this highly pathogenic infection in avian species underscores the need for a preventive vaccine that can be made without eggs. Here, we systematically analyze various forms of recombinant hemagglutinin (HA) protein for their potential efficacy as vaccines. Monomeric, trimeric, and oligomeric H5N1 HA proteins were expressed and purified from either insect or mammalian cells. The immunogenicity of different recombinant HA proteins was evaluated by measuring the neutralizing antibody response. Neutralizing antibodies to H5N1 HA were readily generated in mice immunized with the recombinant HA proteins, but they varied in potency depending on their multimeric nature and cell source. Among the HA proteins, a high-molecular-weight oligomer elicited the strongest antibody response, followed by the trimer; the monomer showed minimal efficacy. The coexpression of another viral surface protein, neuraminidase, did not affect the immunogenicity of the HA oligomer, as expected from the immunogenicity of trimers produced from insect cells. As anticipated, HA expressed in mammalian cells without NA retained the terminal sialic acid residues and failed to bind α2,3-linked sialic acid receptors. Taken together, these results suggest that recombinant HA proteins as individual or oligomeric trimers can elicit potent neutralizing antibody responses to avian H5N1 influenza viruses.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380855570161878666","@type":"Researcher","foaf:name":[{"@value":"Chih-Jen Wei"}],"jpcoar:affiliationName":[{"@value":"Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878660","@type":"Researcher","foaf:name":[{"@value":"Ling Xu"}],"jpcoar:affiliationName":[{"@value":"Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878657","@type":"Researcher","foaf:name":[{"@value":"Wing-Pui Kong"}],"jpcoar:affiliationName":[{"@value":"Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878663","@type":"Researcher","foaf:name":[{"@value":"Wei Shi"}],"jpcoar:affiliationName":[{"@value":"Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878659","@type":"Researcher","foaf:name":[{"@value":"Kevin Canis"}],"jpcoar:affiliationName":[{"@value":"Division of Molecular Biosciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, United Kingdom"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878658","@type":"Researcher","foaf:name":[{"@value":"James Stevens"}],"jpcoar:affiliationName":[{"@value":"Department of Molecular Biology & Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, BCC206, La Jolla, California 92037"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878662","@type":"Researcher","foaf:name":[{"@value":"Zhi-Yong Yang"}],"jpcoar:affiliationName":[{"@value":"Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878661","@type":"Researcher","foaf:name":[{"@value":"Anne Dell"}],"jpcoar:affiliationName":[{"@value":"Division of Molecular Biosciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, United Kingdom"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878656","@type":"Researcher","foaf:name":[{"@value":"Stuart M. Haslam"}],"jpcoar:affiliationName":[{"@value":"Division of Molecular Biosciences, Faculty of Natural Sciences, Imperial College London, London SW7 2AZ, United Kingdom"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878664","@type":"Researcher","foaf:name":[{"@value":"Ian A. Wilson"}],"jpcoar:affiliationName":[{"@value":"Department of Molecular Biology & Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, BCC206, La Jolla, California 92037"}]},{"@id":"https://cir.nii.ac.jp/crid/1380855570161878665","@type":"Researcher","foaf:name":[{"@value":"Gary J. Nabel"}],"jpcoar:affiliationName":[{"@value":"Vaccine Research Center, NIAID, National Institutes of Health, Bldg. 40, Room 4502, MSC-3005, 40 Convent Drive, Bethesda, Maryland 20892-3005"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0022538X"},{"@type":"EISSN","@value":"10985514"}],"prism:publicationName":[{"@value":"Journal of Virology"}],"dc:publisher":[{"@value":"American Society for Microbiology"}],"prism:publicationDate":"2008-07","prism:volume":"82","prism:number":"13","prism:startingPage":"6200","prism:endingPage":"6208"},"reviewed":"false","dc:rights":["https://journals.asm.org/non-commercial-tdm-license"],"url":[{"@id":"https://journals.asm.org/doi/pdf/10.1128/JVI.00187-08"}],"createdAt":"2008-04-17","modifiedAt":"2022-03-05","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360005517233513984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Process development for quantitation and vaccine efficacy assessment of recombinant hemagglutinin-neuraminidase"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168834937472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567370300800","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses"}]},{"@id":"https://cir.nii.ac.jp/crid/1361131644158414464","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1362257544070954752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Soluble Recombinant Hemagglutinin Protein of H1N1pdm09 Influenza Virus Elicits Cross-Protection Against a Lethal H5N1 Challenge in Mice"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1128/jvi.00187-08"},{"@type":"CROSSREF","@value":"10.1128/jvi.01180-21_references_DOI_4MLmNOe6bvizO4n1mGdjV9tjLFs"},{"@type":"CROSSREF","@value":"10.1016/j.procbio.2019.11.018_references_DOI_4MLmNOe6bvizO4n1mGdjV9tjLFs"},{"@type":"CROSSREF","@value":"10.3390/vaccines8030433_references_DOI_4MLmNOe6bvizO4n1mGdjV9tjLFs"},{"@type":"CROSSREF","@value":"10.3389/fimmu.2019.03018_references_DOI_4MLmNOe6bvizO4n1mGdjV9tjLFs"},{"@type":"CROSSREF","@value":"10.3389/fmicb.2019.02031_references_DOI_4MLmNOe6bvizO4n1mGdjV9tjLFs"}]}